Your browser doesn't support javascript.
loading
Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus.
Yanagihara, Ted K; Tepper, Joel E; Moon, Andrew M; Barry, Aisling; Molla, Meritxell; Seong, Jinsil; Torres, Ferran; Apisarnthanarax, Smith; Buckstein, Michael; Cardenes, Higinia; Chang, Daniel T; Feng, Mary; Guha, Chandan; Hallemeier, Christopher L; Hawkins, Maria A; Hoyer, Morten; Iwata, Hiromitsu; Jabbour, Salma K; Kachnic, Lisa; Kharofa, Jordan; Kim, Tae Hyun; Kirichenko, Alexander; Koay, Eugene J; Makishima, Hirokazu; Mases, Joel; Meyer, Jeffrey J; Munoz-Schuffenegger, Pablo; Owen, Dawn; Park, Hee Chul; Saez, Jordi; Sanford, Nina N; Scorsetti, Marta; Smith, Grace L; Wo, Jennifer Y; Yoon, Sang Min; Lawrence, Theodore S; Reig, Maria; Dawson, Laura A.
Affiliation
  • Yanagihara TK; Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Electronic address: tky@unc.edu.
  • Tepper JE; Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
  • Moon AM; Ablative Radiotherapy Modified Delphi Steering Committee; Division of Gastroenterology and Hepatology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
  • Barry A; Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Cork University Hospital, Cork, Ireland.
  • Molla M; Ablative Radiotherapy Modified Delphi Steering Committee; Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Seong J; Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Yonsei University Medical College, Seoul, Republic of Korea.
  • Torres F; Ablative Radiotherapy Modified Delphi Steering Committee; Biostatistics Unit, Medical School, Universitat Auntònoma de Barcelona, Barcelona, Spain.
  • Apisarnthanarax S; Department of Radiation Oncology, University of Washington, Seattle, Washington.
  • Buckstein M; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Cardenes H; Department of Radiation Oncology, Weill Cornell Medicine, New York, New York.
  • Chang DT; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
  • Feng M; Department of Radiation Oncology, University of California, San Francisco, California.
  • Guha C; Department of Radiation Oncology, Montefiore Hospital, New York, New York.
  • Hallemeier CL; Department of Radiation Oncology, Mayo College of Medicine, Rochester, Minnesota.
  • Hawkins MA; Department of Radiation Oncology, University College London, London, England.
  • Hoyer M; Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
  • Iwata H; Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya, Japan.
  • Jabbour SK; Department of Radiation Oncology, Robert Wood Johnson Medical School, Rutgers Cancer Institute, New Brunswick, New Jersey.
  • Kachnic L; Department of Radiation Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
  • Kharofa J; Department of Radiation Oncology, University of Cincinnati Cancer Center, Cincinnati, Ohio.
  • Kim TH; Department of Radiation Oncology, Proton Therapy Center, National Cancer Center, Seoul, Republic of Korea.
  • Kirichenko A; Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania.
  • Koay EJ; Department of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Makishima H; Department of Radiation Oncology, Proton Medical Research Center, University of Tsukuba, Tsukuba, Japan.
  • Mases J; Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Meyer JJ; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Munoz-Schuffenegger P; Department of Hematology-Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile.
  • Owen D; Department of Radiation Oncology, Mayo College of Medicine, Rochester, Minnesota.
  • Park HC; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Saez J; Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Sanford NN; Department of Radiation Oncology, University of Texas, Southwestern, Dallas, Texas.
  • Scorsetti M; Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Milan, Italy.
  • Smith GL; Department of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wo JY; Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Yoon SM; Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Lawrence TS; Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
  • Reig M; Ablative Radiotherapy Modified Delphi Steering Committee; Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain; Liver Cancer Unit, Barcelona Clinic Liver Cancer Group, Barcelona University, Barcelona, Spain. Electronic address: mreig1@clinic.cat.
  • Dawson LA; Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Radiation Medicine Program/University Health Network, University of Toronto, Toronto, Canada.
Pract Radiat Oncol ; 14(2): 134-145, 2024.
Article in En | MEDLINE | ID: mdl-38244026
ABSTRACT

PURPOSE:

External beam radiation therapy (EBRT) is a highly effective treatment in select patients with hepatocellular carcinoma (HCC). However, the Barcelona Clinic Liver Cancer system does not recommend the use of EBRT in HCC due to a lack of sufficient evidence and intends to perform an individual patient level meta-analysis of ablative EBRT in this population. However, there are many types of EBRT described in the literature with no formal definition of what constitutes "ablative." Thus, we convened a group of international experts to provide consensus on the parameters that define ablative EBRT in HCC. METHODS AND MATERIALS Fundamental parameters related to dose, fractionation, radiobiology, target identification, and delivery technique were identified by a steering committee to generate 7 Key Criteria (KC) that would define ablative EBRT for HCC. Using a modified Delphi (mDelphi) method, experts in the use of EBRT in the treatment of HCC were surveyed. Respondents were given 30 days to respond in round 1 of the mDelphi and 14 days to respond in round 2. A threshold of ≥70% was used to define consensus for answers to each KC.

RESULTS:

Of 40 invitations extended, 35 (88%) returned responses. In the first round, 3 of 7 KC reached consensus. In the second round, 100% returned responses and consensus was reached in 3 of the remaining 4 KC. The distribution of answers for one KC, which queried the a/b ratio of HCC, was such that consensus was not achieved. Based on this analysis, ablative EBRT for HCC was defined as a BED10 ≥80 Gy with daily imaging and multiphasic contrast used for target delineation. Treatment breaks (eg, for adaptive EBRT) are allowed, but the total treatment time should be ≤6 weeks. Equivalent dose when treating with protons should use a conversion factor of 1.1, but there is no single conversion factor for carbon ions.

CONCLUSIONS:

Using a mDelphi method assessing expert opinion, we provide the first consensus definition of ablative EBRT for HCC. Empirical data are required to define the a/b of HCC.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pract Radiat Oncol Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pract Radiat Oncol Year: 2024 Type: Article